Channing Global Advisors LLC Cuts Holdings in Danaher Co. (NYSE:DHR)

Channing Global Advisors LLC decreased its position in shares of Danaher Co. (NYSE:DHR) by 28.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,257 shares of the conglomerate’s stock after selling 2,111 shares during the period. Danaher makes up approximately 0.9% of Channing Global Advisors LLC’s investment portfolio, making the stock its 28th biggest position. Channing Global Advisors LLC’s holdings in Danaher were worth $1,216,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. BKM Wealth Management LLC purchased a new position in shares of Danaher during the fourth quarter valued at about $27,000. Wetzel Investment Advisors Inc. purchased a new position in Danaher in the fourth quarter worth about $29,000. OFI Invest Asset Management purchased a new position in Danaher in the third quarter worth about $30,000. Rakuten Securities Inc. purchased a new position in Danaher in the fourth quarter worth about $36,000. Finally, GHP Investment Advisors Inc. grew its position in Danaher by 540.0% in the third quarter. GHP Investment Advisors Inc. now owns 160 shares of the conglomerate’s stock worth $40,000 after acquiring an additional 135 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other Danaher news, CEO Rainer Blair sold 47,175 shares of the stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the sale, the chief executive officer now owns 115,995 shares in the company, valued at approximately $28,908,273.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the sale, the senior vice president now owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. In the last quarter, insiders sold 84,132 shares of company stock worth $21,022,795. Insiders own 11.10% of the company’s stock.

Danaher Stock Performance

NYSE:DHR traded up $1.35 during mid-day trading on Friday, hitting $247.15. The company’s stock had a trading volume of 1,068,379 shares, compared to its average volume of 2,764,344. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $259.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.37. The business’s fifty day moving average is $248.94 and its two-hundred day moving average is $230.88. The stock has a market cap of $183.06 billion, a price-to-earnings ratio of 41.66, a PEG ratio of 4.19 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter in the prior year, the firm earned $2.36 EPS. The company’s revenue for the quarter was down 2.6% on a year-over-year basis. Analysts anticipate that Danaher Co. will post 7.64 EPS for the current fiscal year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be issued a $0.27 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date is Wednesday, March 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. Danaher’s dividend payout ratio is presently 18.31%.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Barclays lifted their price target on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Raymond James boosted their target price on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Bank of America lifted their price target on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research note on Wednesday. TD Cowen boosted their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Six equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $270.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.